Navigation Links
PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:8/24/2011

PRINCETON, N.J., Aug. 24, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV.

In March 2011, Pharmasset presented data from the NUCLEAR study demonstrating that PSI-938 has potent antiviral activity and is generally safe and well tolerated, both as monotherapy and in combination with Pharmasset's lead nucleotide analog, PSI-7977. The NUCLEAR study was conducted in treatment naive subjects with genotype 1 HCV who were treated for 14 days with either PSI-938 or a combination of PSI-938 and PSI-7977 with 92% achieving HCV RNA <15IU/mL, the limit of detection, in the combination arms. Pharmasset plans to initiate QUANTUM, an interferon-free combination trial with PSI-938 and PSI-7977 in the third quarter of 2011.  

Under the FDA Modernization Act of 1997, fast track designation may facilitate the development and expedite the review of a drug candidate that is intended for the treatment of a serious and life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition. PSI-938 was granted the fast track designation primarily due to the need for HCV treatments with improved tolerability, safety and efficacy over the existing standard of care for both treatment-naive and treatment-experienced patients.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... 25, 2015  With the introduction of Elekta,s new ... radiosurgery are now available for more patients with a ... generation stereotactic radiosurgery system for the brain, integrates advanced ... the versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell ... ESTRO Forum in Barcelona . ...
(Date:4/24/2015)... Today, humanity takes a massive step toward reaching ... cronuts: 1-800 CONTACTS announces their new Apple Watch app which ... Two taps. New contacts. From your watch. ... also features LensGauge which helps keep track of how long ... reorder. "Since our inception, we,ve been dedicated to ...
(Date:4/24/2015)... , April 24, 2015  Perrigo Company plc ... its rejection of the unsolicited offer from Mylan NV ... the outstanding shares of Perrigo for $60.00 per share ... ordinary Perrigo share (the "Offer").  The ... per share significantly undervalued the Company and its future ...
Breaking Medicine Technology:New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
... The Barbara Ann Karmanos Cancer Institute announced today that its spin-off ... capital to start the commercialization process of SoftVue, an alternative to mammography. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO ) , ... SoftVue is a tomographic ultrasound imaging and ...
... 24 Genzyme Corp. has signed a consent decree agreeing to correct manufacturing ... to the federal government $175 million in unlawful profits from the sale ... announced today. , , , ... , , ...
Cached Medicine Technology:Karmanos Cancer Institute's Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool 2Karmanos Cancer Institute's Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool 3Karmanos Cancer Institute's Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool 4Karmanos Cancer Institute's Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool 5Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:4/27/2015)... Ticket Down is a reputable source ... Valley Music Theatre and the Isleta Amphitheater. ... Mexico area can celebrate because their favorite performer will ... Buffett will be performing alongside legendary performers, Huey Lewis ... during the summer and fall months of 2015 are ...
(Date:4/27/2015)... April 27, 2015 Telematics Berlin is ... 1&2 suppliers, associations, CE players and the government to ... opened to the car. This year’s panel on connected ... at the European Commission, is an opportunity to hear ... define a European Automotive Security Standard for years to ...
(Date:4/27/2015)... The global coagulation analyzers market is ... developed countries; however, it is expected to witness ... India and Brazil in the next five years. ... by factors such as increasing adoption of automated ... hemostasis analyzers, developments in high-sensitivity point-of-care coagulation analyzers ...
(Date:4/27/2015)... April 27, 2015 Attorney Dan Newlin, of ... serving and protecting his clients, took that commitment to a ... dialing code which makes it easier for existing and potential ... on building his brand and added value to the firm’s ... Chicago area where Newlin has law offices. , “I knew ...
(Date:4/27/2015)... Volpara Solutions today announced the release ... of Breast Imaging’s SBI/ACR Breast Imaging Symposium in ... VolparaDensity, the first breast density assessment tool ... datasets from multiple manufacturers, is already in use ... , The latest version of VolparaDensity ...
Breaking Medicine News(10 mins):Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Dan Newlin Hashtags It With #Dan 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3
... available in French . , ,Hamilton, ... today announced a new study that will increase the ... Member of Parliament for Ancaster-Dundas-Flamborough-Westdale, made the announcement on ... , "This long-term study of 50,000 Canadians will look ...
... Steinem,s 75th Birthday NEW YORK, May 21 ... will be joined by prominent members of the ... of its co-founder Gloria Steinem,s 75th birthday and ... tribute to grassroots women activists and philanthropists who ...
... May 21 Advana Science ( www.advanascience.com ) ... Alzheimer,s disease, has been named scientific advisor to the Company. ... (Volume 16, Issue 3), Dr. Smith was ranked third in ... March 2009. Dr. Smith brings over 20 years of ...
... Most of the current obesity research is not proving ... according to a Deakin University public health expert. , ... better directed at testing possible solutions rather than continuing ... , "It seems counter intuitive, but knowing the causes ...
... The Technology Alliance, UW TechTransfer all partners in ... leaders in health care, business, and community advocacy ... Partnership to Fight Chronic Disease (PFCD). Richard ... General (2002-2006), President of the nonprofit Canyon Ranch ...
... Efficacy Rates in Patients with Challenging Anatomy Consistent ... May 21 New data presented today at ... that Abbott,s market-leading XIENCE V(R) Everolimus Eluting Coronary ... (target lesion revascularization), stent thrombosis and major adverse ...
Cached Medicine News:Health News:Government of Canada supports research to improve the health of future generations of Canadians 2Health News:The Ms. Foundation for Women's 21st Annual Gloria Awards: A National Salute to Women of Vision 2Health News:The Ms. Foundation for Women's 21st Annual Gloria Awards: A National Salute to Women of Vision 3Health News:The Ms. Foundation for Women's 21st Annual Gloria Awards: A National Salute to Women of Vision 4Health News:Leading Alzheimer's Disease Researcher Mark A. Smith, PhD Named Scientific Advisor at Advana Science 2Health News:Leading Alzheimer's Disease Researcher Mark A. Smith, PhD Named Scientific Advisor at Advana Science 3Health News:New direction needed for obesity research, Deakin health expert claims 2Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 2Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 3Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 5Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 6
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Elmed electrosurgical systems for major surgery....
Jewelers bipolar forceps, 10 cm....
European bipolar foot activated forceps....
Medicine Products: